Saturday 17 October 2026
Export LIVN’s income statement to Excel — free account
LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
77.60
0.90
−1.15%
Follow LIVN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
23.83 | 32.26 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.07 | 2.42 | 2.42 | 2.12 | |
P/FCF ratio |
29.69 | 21.07 | 18.94 | 15.21 | |
P/Operating CF |
67.88 | 228.44 | 40.73 | 33.64 | |
P/B ratio |
3.41 | 2.87 | 2.80 | 2.47 | |
Price to Tangible BV |
13.73 | 17.28 | 18.94 | 21.73 | |
EV/Sales |
2.92 | 2.25 | 2.23 | 1.96 | |
EV/EBITDA |
15.76 | 11.73 | 10.98 | 9.65 | |
EV/Operating CF |
17.24 | 13.13 | 12.18 | 10.57 | |
EV/FCF |
28.23 | 19.54 | 17.48 | 14.08 | |
Quick Ratio |
1.06 | 1.01 | 1.05 | 1.04 | |
Current Ratio |
1.45 | 1.33 | 1.36 | 1.33 | |
Net Debt/EBITDA |
(3.07) | (4.07) | (4.10) | (2.82) | |
Debt/Assets |
11.11% | 11.44% | 14.45% | 16.99% | |
Debt/Equity |
0.22 | 0.24 | 0.31 | 0.38 | |
Asset Turnover |
0.57 | 0.56 | 0.54 | 0.53 | |
Operating CF/Net income |
0.61 | 0.68 | 2.67 | 3.18 | |
Capex/Depreciation |
(1.36) | (0.70) | (1.22) | (1.09) | |
Interest Coverage |
6.90 | 5.00 | 5.19 | 4.97 | |
Research and Development Expense of Revenue |
13.74% | 16.20% | 14.44% | 13.58% | |
Selling, General and Administrative Expense of Revenue |
40.48% | 39.63% | 39.72% | 38.72% | |
Intangible Assets out of Total Assets |
0.38 | 0.40 | 0.39 | 0.40 | |
Share Based Compensation of Revenue |
4.32% | 2.28% | 2.60% | 2.78% | |
Graham Net Nets |
(0.06) | (0.08) | (0.09) | (0.11) | |
Graham Number |
43.26 | 31.33 | 0.00 | 0.00 | |
Earnings Yield |
4.20% | 3.10% | (7.23%) | (7.62%) | |
Free Cash Flow Yield |
3.37% | 4.75% | 5.28% | 6.58% | |
Revenue per Share |
7.11 | 6.62 | 6.62 | 6.55 | |
Operating CF per Share |
1.21 | 0.28 | 1.51 | 1.56 | |
Capex per Share |
(0.57) | (0.26) | (0.46) | (0.42) | |
Free Cash Flow per Share |
0.64 | 0.02 | 1.05 | 1.14 | |
Cash per Share |
9.40 | 9.87 | 11.65 | 11.83 | |
Shareholders Equity per Share |
24.11 | 22.15 | 22.00 | 21.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
24.11 | 22.15 | 22.00 | 21.18 | |
Free Cash Flow |
35.04 | 0.93 | 57.45 | 62.18 | |
Working Capital |
318.04 | 251.76 | 293.54 | 269.56 | |
Capital Expenditures |
(31.55) | (14.29) | (24.95) | (22.88) | |
Net Current Asset Value |
(290.49) | (290.79) | (304.45) | (303.20) | |
EV/EBIT |
22.91 | 16.77 | 15.53 | 13.67 | |
Capex to Sales |
0.08 | 0.04 | 0.07 | 0.06 | |
Price to Operating Income |
24.10 | 18.08 | 16.83 | 14.76 | |
| Other line items | |||||
Average Receivables |
225.75 | 215.68 | 204.57 | 204.37 | |
Average Payables |
95.16 | 93.39 | 83.44 | 83.02 | |
Average Inventory |
168.98 | 159.76 | 156.13 | 164.90 | |
Average Assets |
2,573.78 | 2,537.55 | 2,556.22 | 2,539.77 | |
Average Common Equity |
1,224.08 | 1,122.81 | 1,260.12 | 1,233.64 |
Columns are period end dates